Total Revenue
AbbVie Total Revenue decreased by 9.7% to $15.00B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.4%, from $13.34B to $15.00B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 2.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.96B | $14.34B | $14.89B | $13.54B | $14.58B | $14.81B | $15.12B | $12.23B | $13.87B | $13.93B | $14.30B | $12.31B | $14.46B | $14.46B | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B |
| QoQ Change | — | +2.7% | +3.8% | -9.1% | +7.7% | +1.6% | +2.1% | -19.2% | +13.4% | +0.4% | +2.7% | -13.9% | +17.5% | -0.0% | +4.4% | -11.6% | +15.6% | +2.3% | +5.3% | -9.7% |
| YoY Change | — | — | — | — | +4.5% | +3.3% | +1.6% | -9.7% | -4.9% | -6.0% | -5.4% | +0.7% | +4.3% | +3.8% | +5.6% | +8.4% | +6.6% | +9.1% | +10.0% | +12.4% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Skyrizi | $2.73B | $3.21B | $3.78B | $3.43B | $4.42B | $4.71B | $5.01B | $4.48B |
| Rinvoq | $1.43B | $1.61B | $1.83B | $1.72B | $2.03B | $2.18B | $2.37B | $2.12B |
| All other | $810.00M | $726.00M | $752.00M | $747.00M | $603.00M | $660.00M | $617.00M | $1.03B |
| Botox Therapeutic | $814.00M | $848.00M | $873.00M | $866.00M | $928.00M | $985.00M | $990.00M | $1.01B |
| Vraylar | $774.00M | $875.00M | $924.00M | $765.00M | $900.00M | $934.00M | $1.02B | $905.00M |
| Venclexta | $637.00M | $677.00M | $655.00M | $665.00M | $691.00M | $726.00M | $710.00M | $770.00M |
| Humira | $2.81B | $2.23B | $1.68B | $1.12B | $1.18B | $993.00M | $1.25B | $688.00M |
| Botox Cosmetic | $729.00M | $671.00M | $687.00M | $556.00M | $692.00M | $637.00M | $717.00M | $668.00M |
| Imbruvica | $833.00M | $828.00M | $848.00M | $738.00M | $754.00M | $706.00M | $671.00M | $556.00M |
| Mavyret | $369.00M | $302.00M | $291.00M | $306.00M | $375.00M | $312.00M | $324.00M | $351.00M |
| Ubrelvy | $231.00M | $269.00M | $303.00M | $240.00M | $338.00M | $354.00M | $339.00M | $339.00M |
| Qulipta | $150.00M | $176.00M | $201.00M | $193.00M | $267.00M | $288.00M | $288.00M | $296.00M |
| Other Aesthetics | $318.00M | $310.00M | $332.00M | $315.00M | $327.00M | $303.00M | $320.00M | $286.00M |
| Linzess | $221.00M | $234.00M | $233.00M | $148.00M | $258.00M | $326.00M | $175.00M | $283.00M |
| Juvederm Collection | $343.00M | $258.00M | $279.00M | $231.00M | $260.00M | $253.00M | $249.00M | $232.00M |
| Vyalev | — | — | — | $63.00M | $98.00M | $138.00M | $183.00M | $201.00M |
| Elahere | — | — | — | $179.00M | $159.00M | $170.00M | $182.00M | $198.00M |
| Other Neuroscience | $80.00M | $84.00M | $100.00M | $59.00M | $55.00M | $46.00M | $47.00M | $125.00M |
| Epkinly | $36.00M | $43.00M | $40.00M | $51.00M | $70.00M | $69.00M | $81.00M | $83.00M |
| Alphagan Combigan | $49.00M | $62.00M | $78.00M | $60.00M | $36.00M | $47.00M | $54.00M | — |
| Duodopa | $113.00M | $111.00M | $108.00M | $96.00M | $97.00M | $96.00M | $92.00M | — |
| Lumigan Ganfort | $103.00M | $116.00M | $119.00M | $106.00M | $103.00M | $97.00M | $104.00M | — |
| Other Eye Care | $225.00M | $207.00M | $215.00M | $217.00M | $250.00M | $248.00M | $294.00M | — |
| Ozurdex | $124.00M | $119.00M | $120.00M | $123.00M | $125.00M | $117.00M | $128.00M | — |
| Restasis | $32.00M | $21.00M | $114.00M | — | — | — | — | — |
| Total | $14.46B | $14.46B | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B |
Alphagan Combigan, Duodopa, Lumigan Ganfort, Other Eye Care, Ozurdex, Restasis were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is AbbVie's total revenue?
- AbbVie (ABBV) reported total revenue of $15.00B in Q1 2026.
- How has AbbVie's total revenue changed year-over-year?
- AbbVie's total revenue increased by 12.4% year-over-year, from $13.34B to $15.00B.
- What is the long-term trend for AbbVie's total revenue?
- Over 4 years (2021 to 2025), AbbVie's total revenue has grown at a 2.1% compound annual growth rate (CAGR), from $56.20B to $61.16B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.